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past, the prevalence of other species has been increasing recently. The Candida infection scale shows that patterns of the preponderance are now on the side of the non-albicans (C. glabrata, C. tropicalis, Candida parapsilosis and Candida krusei) instead of C. albicans. For example, it has been reported that Candida glabrata is the second most common agent of the vaginal candidiasis. [11] [12] [13] In addition to, variation among epidemiological patterns, has also been reported that the resistance of the Candida species to conventional treatment is now increasing. [7, 14] Since most of the hospitals have not enough facilities to detect other species of the Candida, they can only differentiate C. albicans and non-albicans. The routine diagnostic methods are usually limited to differentiate Candida species. This limitation is a result of either the lack of definitive diagnostic method or inability of the method. Candida dubliniensis was first identified in 1995 from clinical samples and has some phenotypic similarities (germ tube [+], generating Klamidospora forms) with C. albicans and is very difficult to be differentiated using standard diagnostic methods. [15] In the late 1990s, it was reported that the strains (C. dubliniensis) were susceptible to the antifungals, but in recent years, fluconazole-resistant strains and also multidrug resistance has been reported. [16] [17] [18] [19] Nowadays, most laboratories use routine diagnostic procedures to differentiate the strains whether they are C. albicans or non-albicans, and the choice of antifungal drug is made empirically. To determine the distribution of Candida species, it is necessary to know choice of the antifungal drugs according to the antifungal resistance patterns and the infection control procedures amongst the various health associations in different cities and countries. The distribution of Candida species and antifungal resistance patterns can vary between cities and even between the health associations in the same city. Knowledge about the distribution of Candida species and the drug resistance patterns is very important to prevent the spread of multidrug-resistant strains and for effective treatment. [17, 20] It is observed that opportunistic Candida infections have increased significantly in recent years. The prevalence of Candida infections have increased particularly in immunosuppressive people like patients with HIV, cancer or through widespread use of immunosuppressive chemotherapy. The identification of Candida species -the cause of the disease -is of high importance because the pathogenicity and antifungal susceptibility of Candida differ according to species. [11] With the current study, we aimed at identifying the distribution of Candida species isolated from clinical samples using an automatic system for phenotypic identification and restriction fragment length polymorphism (RFLP) method based on Msp I and Bln I restriction digestion of ITS1 and ITS2 region PCR amplicons.
mateRIals and methods

Collecting the samples and microbiologic culture
The samples (urine, wound swab, vaginal swab, sputum, bronchoalveolar lavage fluid, catheters, blood, thoracocentesis fluid and sperma) were taken from the patients who received treatment in several polyclinics and departments of Mustafa Kemal University Medical School, Health Practice and Research Hospital and were analysed in microbiology laboratory. Origins of the Strains were isolated from urine samples (79%), vaginal swap samples (11%), wound samples (3%), blood samples (2%), bronchoalveolar lavage samples (1%), catheter samples (1%), sputum samples (1%), thoracentesis samples (1%) and sperma samples (1%). The samples which were collected from different departments were inoculated onto Sabouraud dextrose agar. The plates were incubated at 37°C for 48 h. Colony count ≥10 5 cfu/ml in urine cultures and pure or predominant growth in other cultures were evaluated as pathogenicity criteria. Germ tube-positive strains were microbiologically considered as C. albicans. Others (non-albicans) were analysed with automatised system (VITEK-2, bioMerieux, France) and kits used for biochemical tests. Moreover, antifungal susceptibility of the isolated candidal strains was measured by AST-YS06 (bioMerieux, France) kit as recommended by commercial company.
The C. albicans (ATCC 90028), C. krusei (ATCC 6258), C. parapsilosis (ATCC 22019), C. tropicalis (ATCC 22019) and C. glabrata (ATCC 32554) strains were used as standard strains for the aim of quality control. In accordance with the Clinical and Laboratory Standards Institute criteria, the minimum inhibitory concentration (MIC) value of antifungal drugs for the Candida species was evaluated as susceptible, intermediate and resistant. Since the MIC value of the amphotericin B was not standard, the value MIC ≥2 mg/l was taken as resistant (R) (National Committee for Clinical Standards 2002). [15] Phenotypically identified strains were reserved for PCR-RFLP analyses. For these analyses, first genomic DNA extraction and PCR amplification of the strains were performed, and after restriction of the amplification products by Msp I and Bln I enzymes, restriction fragment analyses allowed genotypic identification.
Genomic DNA extraction and polymerase chain reaction amplification
Commercially provided ZR Fungal/Bacterial DNA Kit (Zymo Research) was used for genomic DNA extraction.
PCR amplification was performed using ITS1 and ITS4 primers from the isolated genomic DNA samples. PCR mix was prepared before this process. Accordingly, each of the Eppendorf tube contained 36.8 µl distilled water, 5 µl buffer, 1 µl dNTP, 0.2 µl Taq DNA polymerase, 3 µl MgCl 2 , 1 µl forward primer and 1 µl reverse primer for each patient sample. It was vortexed and after 2 µl genomic DNA was added. A total of 50 µl volume was obtained and the amplification cycle was performed. The PCR procedure was as follows: initial denaturation step at 94°C for 5 min followed by 35 cycles consisting of denaturation (94°C for 1 min), annealing (56°C for 1 min) and extension (72°C for 1 min), followed by a final extension step at 72°C for 7 min.
Scanning the polymerase chain reaction products with agarose gel electrophoresis method
After PCR process, the existence of the amplification products was detected by running them in agarose gel (2%) and by screening the bands through Wealtec, Dolphin-View, USA, screening device.
Restriction fragment length polymorphism
The PCR products, which were obtained after amplification, were cut by Msp I and Bln I restriction enzymes for RFLP analyses. The target area of these enzymes on the DNA molecules were as follows: the enzyme Msp I recognised and cleaved the sequence CCGG while Bln I recognised the sequence CCTAGG. [21] Restriction enzyme analyses with Msp I and Bln I A total volume of 25 µl with PCR amplification product and Msp I/Bln I was prepared as follows: digestion reactions were performed for each of the selected restriction enzymes (Msp I and Bln I) in a total volume of 25 µl containing 5 µl of × 10 reaction buffer, 1 µl of each restriction enzyme (10 U/µl), 10 µl of the PCR products of each sample and 9 µl of distilled water. Restriction process was done at 37°C and after 4 h incubation.
Analyses of restricted products
The control of the restricted products was made in agarose gel with 3% concentration. Ten microlitres of PCR products which were cut by Msp I and Bln I and 3 µl loading dye were mixed and loaded into gel. Restricted products were run with 100 bp DNA ladder and then screened by ultraviolet transilluminator (Wealtec, Dolphin-View, USA) and checked.
Results
In the study, the distribution of strains of Candida according to the departments was as follows: 33 (22%) isolates from the internal diseases Intensive Care Unit, 27 (18%) isolates from the department of gynaecology and obstetrics, 19 (12.6%) isolates from the department of internal diseases, 18 (12%) isolates from the surgery Intensive Care Unit, 11 (7.3%) isolates from the department of urology, 8 (5.3%) isolates from the department of brain and nerve surgery, 6 (4%) isolates from the department of chest diseases, 5 (3.3%) isolates from paediatric department, 4 (2.6%) isolates from the department of internal diseases -endocrinology, orthopaedics and traumatology, infectious diseases and dermatology, 2 (1.3%) isolates from the coroner Intensive Care Unit and physical therapy and rehabilitation and 1 (0.6%) isolate from the department of cardiology, paediatric neurology and eye diseases.
According to the phenotypic identification, the distribution of isolates were found to be as 48.6% (73/150) for C. albicans, 17 According to the genotypic identification of the strains, the distribution of isolates according to departments, is stated below: of 33 Candida spp. which were isolated from internal diseases Intensive Care Unit, 15 (45.4%) were C. albicans, 5 (15.1%) were C. tropicalis, 5 (15.1%) were C. glabrata and 3 (9.09%) were C. parapsilosis. When the distribution of species that were obtained from gynaecology and obstetrics department which provided the second most common isolates following internal diseases Intensive Care Unit was examined (a total of 27 isolates), strains isolated at the highest ratio were C. albicans, C. glabrata, C. tropicalis, C. krusei and C. parapsilosis; 14 (51.8%), 5 (18.5%), 3 (11.1%), 2 (7.4%) and 2 (7.4%), respectively. The distribution of species obtained from internal diseases department where a total of 19 candidal strains were isolated, was as follows: C. albicans 47.3% (9/19), C. tropicalis 21.05% (4/19) and C. glabrata 15.7% (3/19) . The distribution of species identified genotypically according to departments is shown in Table 1 .
In the study, C. albicans was the most commonly isolated species, but there was a discrepancy of 5.5% between conventional (phenotypic) and PCR-RFLP methods. Similarly, there were also discrepancies in the identification of C. tropicalis, C. glabrata and C. parapsilosis by 21.4%, 16.0% and 33.0%, respectively [ Table 2 ]. When distribution of species obtained genotypically with the use of restriction enzymes Msp I and Bln I was examined, it was observed that C. albicans was 45.3% and C. glabrata was 19.3% while C. parapsilosis and C. krusei were less prevalent with a ratio of 5.3% both, which meant that RFLP method was not able to identify 10% of the isolates to species level [ Table 3 ].
When distribution of species according to the clinical origins of isolates was examined, RFLP analyses revealed that 47.5% of Candida was C. albicans (56/118), 19 .4% was C. glabrata (23/118), 14.4% was C. tropicalis (17/118), 4.2% was C. krusei (5/118), 3.3% was C. parapsilosis (4/118) and 0.8% was C. lusitaniae (1/118) in urine samples and 10.1% (12/118) of Candida could not be detected to species level. Again, in vaginal swabs where strains were isolated most after urine samples, C. albicans was the second most found Candida by 43.8% (7/16), C. tropicalis and C. glabrata were of 18.7% (3/16), C. parapsilosis of 12.5% (2/16) and C. krusei of 6.2% (1/16). Only 1 vaginal sample (6.2%) could not be characterised to species level. The distribution of species according to the clinical samples is shown in Table 4 .
Amphotericin B, fluconazole and voriconazole antifungal susceptibility patterns of Candida species which were isolated from 37 patients who received a treatment from different departments were assessed. Table 5 demonstrated the MIC values of Candida species. Fluconazole resistance in one isolate each of C. albicans and one C. glabrata strains can be clearly seen in Table 5 .
PCR amplification of 150 clinical samples was performed using ITS1 and ITS4 primers in the study. In the study, the restriction products which were exposed to Msp I restriction enzyme between the size of 261 bp and 557 bp were evaluated. [20] After the analyses of the restriction products, 68 C. albicans species (45.3%), 29 C. glabrata species (19.3%), 22 C. tropicalis species (14.6%), 8 C. parapsilosis species (5.3%), 8 C. krusei species (5.3%) and 1 C. lusitaniae species (0.6%) were found. Other strains were accepted as Candida spp. 
dIscussIon
With severe infections and having antifungal susceptibility differences, identification of pathogen Candida has a significant importance. [3, 7] Through this study, we aimed to identify the distribution of Candida species isolated from clinical samples using an automatic system for phenotypic identification and RFLP method based on Msp I and Bln I restriction digestion of ITS1 and ITS2 region PCR amplicons. Furthermore, we aimed to determine the antifungal susceptibility of Candida to drugs which are routinely used (amphotericin B, flucytosine, fluconazole and voriconazole).
Candida infections are reported as the third main cause of the infections which occur in Intensive Care Units and fourth main cause of the bloodstream infections. Candida infections are very important as they sense that they prolong hospital stay and increase the morbidity and mortality. The most common species of Candida is C. albicans which is isolated from both healthy individuals and patients. [22, 23] The studies carried out over the last two decades have revealed that >80% of all forms of human candidiasis isolates were C. albicans. On the other hand, particularly in recent years, the infections due to other non-albicans Candida have been to be on the rise. [24, 25] It has been reported that the significant increase of non-albicans Candida as a pathogenesis of human candidiasis might be related with the development of diagnostic methods. The best example of this is that the CHROMagar chromogenic media are at least as successful as other routine molecular methods in identifying Candida species which are isolated from fungaemia cases. [26] Identification of etiological agent and antifungal drug choice is crucial for Candida infections. Unfortunately, antifungal susceptibility tests are not available in many healthcare centres today. Identification of intrinsically resistant strains or strains which are highly resistant to many antifungals is mainly advisor to empiric treatment. When compared with C. albicans, non-albicans Candida are more resistant to antifungals, and therefore, it is estimated that they are isolated more common in Candida infections recently. [22] In this study, the urine samples were the ones from which Candida were isolated most (78.6%), followed by strains isolated from vaginal swabs (11.3%) and wound swabs (3.3%), respectively. It has been reported that the candiduria is more prevalent in inmates. But recently, with the increasing risk factors as a pathogen, candiduria is isolated more. [27] The risk factors of candiduria include use of long-term broad-spectrum antibiotics, long duration of hospital stay, metabolic diseases and immunosuppressive treatments. In a study, it was reported that 21.3% of catheter related infections are caused by Candida. [28, 29] Catheter is a common route for pathogens to enter urinary tract, and long-term catheterisation can cause colonisation of microorganisms. According to a study of a patient with candidiasis, C. albicans was the most common isolate (51%) and C. glabrata was the second most common isolate by 16%. [30] In a study which included 250 catheterised patients, both phenotypic and genotypic analyses were performed to determine the cause of candiduria to detect candiduria prevalence. To identify the yeasts, Firstly, to identify the yeasts, phenotypic methods such as germ tube method, hypha and pseudohypha or chlamydospore growth on CMA + TW80 and CHROMagar Candida were performed and evaluated. Genomic DNA of all species was first analysed with PCR and then RFLP methods employed. As a result of urine analyses of 95 females and 145 males, Candida spp. was isolated from 40 samples. The prevalence of candiduria was estimated as 16%. [31] In our study, it is clear that the distribution of species by identification of isolates based on PCR-RFLP concurred with literature. [31] We isolated 57 C. albicans from 118 urine samples (48.3%).
The second most isolated species was C. glabrata and the third was C. tropicalis by 19.4% and 14.4%, respectively. As in the urinary samples, C. albicans was again the most isolated species from vaginal swabs (37.5%; 6/16) with C. tropicalis and C. glabrata followed by 18.7% (3/16) both. Apart from these species, C. parapsilosis (12.5%) and C. krusei (6.2%) were isolated from vaginal samples.
The range and the distribution of pathogen Candida depend on anatomical localization and environmental conditions.
Non-albicans Candida are mostly isolated from throat and vagina. [32] The choice of antifungal drug is made according to clinical condition, infected area, pharmacodynamics and pharmacokinetics. Fluconazole is an antifungal drug and the best choice for urinary tract infections and also affects many of Candida. In concordance with literature, in our study, non-albicans Candida were more resistant to antifungals than C. albicans. [33] Many methods are available to identify Candida species. These methods can be divided into two main groups: phenotypic and genotypic methods. In our study, we characterized the isolated Candida from the clinical samples using both phenotypic method and genotypic PCR-RFLP method. According to phenotypic method, C. albicans was the most isolated species (48.6% When these two methods were compared, 4 (5.6%) of the 72 samples which were identified as C. albicans with phenotypic method were not C. albicans according to genotypic method. This discrepancy amongst C. albicans was clearer and more evident amongst other non-albicans Candida.
For example, 21.4% (22/28) of the 28 isolates identified as C. tropicalis with phenotypic method were not detected as C. tropicalis. Likewise, a total of 25 C. glabrata were identified with phenotypic method while 29 C. glabrata were identified with genotypic methods. The highest discrepancy of the methods used for identifying the species occurred between C. parapsilosis and C. krusei by 33.3%. Since these two species are known to be resistant to antifungals, the importance of true and fast identification is evident.
In our study, there were also similar discrepancies between these two methods in terms of identifying rarely isolated species. For example, one C. kefyr, one C. lipolytica and one C. famata isolates were phenotypically identified, but none of them was verified as C. kefyr, C. lipolytica or C. famata genotypically. The only consistence between these methods was seen in identifying C. lusitaniae phenotypically and genotypically.
Furthermore, 6% of all isolates could not be identified phenotypically whereas 9.3% of all strains could not be identified genotypically. We are of the opinion that we may be able to identify the isolates which are genotypically non-identified by increasing the number of restriction enzymes, which thus increases the sensitivity.
C. albicans is the main cause of most of Candida infections, but it has been reported that the prevalence of C. glabrata and C. krusei, more resistant to azoles, has significantly increased recently. [34] The early diagnosis of invasive fungal infections is highly important to lower the rate of mortality. Though new molecular methods were reported recently, there is always a demand for a simple, fast and cost-effective method. In a study, the region ITS1-5.8S-ITS2 (510-879 bp) of rDNA was amplified by ITS1 and ITS4 primers, RFLP was then performed and thus the most common 6 species of Candida were identified. [35] In our study, ITS1 and ITS2 regions were amplified only using Msp I and Bln I restriction enzymes, 6 species of Candida isolated from Candida infections were successfully identified. 
